Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Primary antibodies

Anti-Human CD367/CLEC4A Polyclonal Antibody (HV145014)

Price(USD):
Spec:
  • 50ug
  • 100ug
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.HV145014
Description
Anti-Human CD367/CLEC4A Polyclonal Antibody (HV145014) is a rabbit polyclonal antibody detecting CLEC4A in ELISA, IHC, WB. Suitable for Human.
Highlights
  • Affinity Purified — Minimal background and high purity for reliable results.
  • Multi-Application — Validated across multiple applications.
Species reactivityHuman
ApplicationsELISA, IHC, WB
Host speciesRabbit
IsotypeIgG
Clonality Polyclonal
Immunogen E. coli - derived recombinant Human CD367/CLEC4A (Gln70-Leu237).
Target C-type lectin domain family 4 member A, C-type lectin DDB27, C-type lectin superfamily member 6, Dendritic cell immunoreceptor, Lectin-like immunoreceptor, CD367, CLEC4A, CLECSF6, DCIR, LLIR, HDCGC13P
Purification Purified by antigen affinity column.
Accession Q9UMR7
Form Liquid
Storage buffer 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information
Application Dilution
ELISA 1:5000-1:20000
IHC 1:50-1:500
WB 1:500-1:2000
Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Background

C-type lectin domain family 4 member A (CD367/CLEC4A) is a ~27 kDa protein. C-type lectin receptor that binds carbohydrates mannose and fucose but also weakly interacts with N-acetylglucosamine (GlcNAc) in a Ca(2+)-dependent manner. Involved in regulating immune reactivity. Once triggered by antigen, it is internalized by clathrin-dependent endocytosis and delivers its antigenic cargo into the antigen presentation pathway resulting in cross-priming of CD8(+) T cells. This cross-presentation and cross-priming are enhanced by TLR7 and TLR8 agonists with increased expansion of the CD8(+) T cells, high production of IFNG and TNF with reduced levels of IL4, IL5 and IL13. In plasmacytoid dendritic cells, inhibits TLR9-mediated IFNA and TNF production.

1. Nagae, M. et al. (2016) FEBS letters 590, 1280-8. PMID: 27015765
2. Bates, EE. et al. (1999) Journal of immunology (Baltimore, Md. : 1950) 163, 1973-83. PMID: 10438934
3. Meyer-Wentrup, F. et al. (2008) Blood 111, 4245-53. PMID: 18258799
4. Klechevsky, E. et al. (2010) Blood 116, 1685-97. PMID: 20530286
Note For research use only.
Images
References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list